DNA, D(3'-AMINO-3'-DEOXY-P-THIO)(T-A-G-G-G-T-T-A-G-A-C-A-A), 5'-(O-(2-HYDROXY-3-((1-OXOHEXADECYL)AMINO)PROPYL) HYDROGEN PHOSPHOROTHIOATE)
Previously Treated Childhood Rhabdomyosarcoma
Children's Oncology Groupnucleic_acidPhase 2Dormant
CCC
53/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 38/ 100
- Competitive Position
- 95/ 100
Competitive context
59 Active assets in the Previously Treated Childhood Rhabdomyosarcoma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Irinotecan Eisai Inc. | Phase 2 | BBB |
Ipilimumab Children's National Research Institute | Phase 2 | BB |
CALCIUM PHOSPHATE Children's Oncology Group | Phase 3 | BB |
Irinotecan Milton S. Hershey Medical Center | Phase 2 | BB |
Eloxatin National Cancer Institute (NCI) | Phase 2 | BB |
View all 50 →
Same molecule, other indications
DNA, D(3'-AMINO-3'-DEOXY-P-THIO)(T-A-G-G-G-T-T-A-G-A-C-A-A), 5'-(O-(2-HYDROXY-3-((1-OXOHEXADECYL)AMINO)PROPYL) HYDROGEN PHOSPHOROTHIOATE) is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →